WuXi PharmaTech (WX) Tops Q4 EPS by 10c; Guides Q1, FY12 Revs
Tweet
Share
E-mailGet Alerts WX Hot Sheet
Join SI Premium – FREE
WuXi PharmaTech (NYSE: WX) reported Q4 EPS of $0.36, $0.10 better than the analyst estimate of $0.26. Revenue for the quarter came in at $108.5 million versus the consensus estimate of $106.87 million.
Sees FY2012 revenue of $468-$488 million, versus the consensus of $464.6 million.
Sees Q1 2012 revenue of $114-$117 million, versus the consensus of $108 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
Sees FY2012 revenue of $468-$488 million, versus the consensus of $464.6 million.
Sees Q1 2012 revenue of $114-$117 million, versus the consensus of $108 million.
For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Ideal Power (IPWR) Tops Q2 EPS by 2c
- Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
